EMAIL THIS PAGE TO A FRIEND

American journal of kidney diseases : the official journal of the National Kidney Foundation

Effect of Moderate Aerobic Exercise Training on Endothelial Function and Arterial Stiffness in CKD Stages 3-4: A Randomized Controlled Trial.


PMID 25960303

Abstract

Evidence of a beneficial effect of exercise training on mediators of vascular disease is accumulating in chronic kidney disease (CKD), but its effect on vascular function in vivo still has to be established. The present study was designed to investigate whether a formal aerobic exercise training program improves peripheral endothelial function in patients with CKD stages 3 to 4. Randomized controlled trial with a parallel-group design. 48 patients with CKD stages 3 to 4 without established cardiovascular disease were randomly assigned to either an exercise training program or usual care. 40 patients completed the study (exercise training, 19; usual care, 21). The 3-month home-based aerobic training program consisted of 4 daily cycling sessions of 10 minutes each at a target heart rate, calculated as 90% of the heart rate achieved at the anaerobic threshold. Patients in the usual-care group were given standard therapy. The primary outcome was peripheral endothelial function. Secondary outcomes were aerobic capacity, arterial stiffness, numbers of endothelial (EPCs) and osteogenic progenitor cells (OPCs), migratory function of circulatory angiogenic cells, and health-related quality of life. Endothelial function was assessed with flow-mediated dilation of the brachial artery, aerobic capacity by peak oxygen uptake (VO(2peak)), arterial stiffness by carotid-femoral pulse wave velocity, numbers of EPCs and OPCs by flow cytometry, circulatory angiogenic cell function by an in vitro migratory assay, and quality of life by the Kidney Disease Quality of Life-Short Form questionnaire. Exercise training significantly improved VO(2peak) and quality of life, but not in vivo vascular function (flow-mediated dilation and carotid-femoral pulse wave velocity) or cellular markers for vascular function (EPC and OPC count and circulatory angiogenic cell migratory function). Short duration and intermittent nature of the exercise intervention. In patients with CKD stages 3 to 4 without overt cardiovascular disease, 3 months of aerobic exercise training improved VO(2peak) and quality of life, without altering endothelial function or arterial stiffness.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB4300356
Anti-KDR (Ab-1175) antibody produced in rabbit, affinity isolated antibody
SAB4300357
Anti-KDR (Ab-1214) antibody produced in rabbit, affinity isolated antibody
SAB4300358
Anti-KDR (Ab-951) antibody produced in rabbit, affinity isolated antibody
SAB2900238
Anti-KDR (AB1) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2900239
Anti-KDR (AB2) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2101239
Anti-KDR antibody produced in rabbit, affinity isolated antibody
V1014 Anti-Vascular Endothelial Growth Factor Receptor 2 antibody produced in goat, affinity isolated antibody, lyophilized powder
GW21181 Anti-VEGFR-2 antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
SAB4300657
Anti-VEGFR2 (Ab-1059) antibody produced in rabbit, affinity isolated antibody
SAB4501645
Anti-VEGFR2 antibody produced in rabbit, affinity isolated antibody
SAB4501642
Anti-VEGFR2, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB4501643
Anti-VEGFR2, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB4501644
Anti-VEGFR2, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB4500965
Anti-VEGFR2, C-Terminal antibody produced in rabbit, affinity isolated antibody
WH0003791M1
Monoclonal Anti-KDR antibody produced in mouse, clone 2A2, purified immunoglobulin, buffered aqueous solution
SAB1404004
Monoclonal Anti-KDR antibody produced in mouse, clone 4A2, purified immunoglobulin, buffered aqueous solution